TY - JOUR
T1 - ABO-incompatible liver transplantation for severe hepatitis B patients
AU - Zhou, Jian
AU - Ju, Weiqiang
AU - Yuan, Xiaopeng
AU - Jiao, Xingyuan
AU - Zhu, Xiaofeng
AU - Wang, Dongping
AU - He, Xiaoshun
N1 - Publisher Copyright:
© 2015 Steunstichting ESOT.
PY - 2015/7/1
Y1 - 2015/7/1
N2 - Effect of ABO-incompatible liver transplantation on patients with severe hepatitis B (SHB) remains unclear. Herein, we summarized 22 cases with SHB in whom were performed emergency liver transplantation from ABO-incompatible donors. The immunosuppressive protocol consisted basiliximab, tacrolimus, steroids and mycophenolate mofetil. The mean MELD score was 35.2 ± 7.1. Major complications included rejection, infections, biliary complications, hepatic artery thrombosis or stenosis and portal vein thrombosis. Patient survival rates were 40.9%, 78.9% and 82.3% in 1 year, 29.2%, 66.8% and 72.9% in 3 years, and 21.9%, 60.1% and 62.5% in 5 years for ABO-incompatible, ABO-compatible and ABO-identical groups. Graft survival rates were 39%, 78.9% and 82.3% in 1 year, 27.8%, 66.4% and 71.1% in 3 years, and 20.9%, 57.9% and 61.0% in 5 years for incompatible, compatible and identical ABO graft-recipient match. The 1-, 3-, 5-year graft and patient survival rates of ABO-incompatible were distinctly lower than that of ABO-compatible group (P < 0.05). Our results suggested that ABO-incompatible liver transplantation might be a life-saving procedure for patients with SHB as a promising alternative operation when ABO-compatible donors are not available and at least bridges the second opportunity for liver retransplantation.
AB - Effect of ABO-incompatible liver transplantation on patients with severe hepatitis B (SHB) remains unclear. Herein, we summarized 22 cases with SHB in whom were performed emergency liver transplantation from ABO-incompatible donors. The immunosuppressive protocol consisted basiliximab, tacrolimus, steroids and mycophenolate mofetil. The mean MELD score was 35.2 ± 7.1. Major complications included rejection, infections, biliary complications, hepatic artery thrombosis or stenosis and portal vein thrombosis. Patient survival rates were 40.9%, 78.9% and 82.3% in 1 year, 29.2%, 66.8% and 72.9% in 3 years, and 21.9%, 60.1% and 62.5% in 5 years for ABO-incompatible, ABO-compatible and ABO-identical groups. Graft survival rates were 39%, 78.9% and 82.3% in 1 year, 27.8%, 66.4% and 71.1% in 3 years, and 20.9%, 57.9% and 61.0% in 5 years for incompatible, compatible and identical ABO graft-recipient match. The 1-, 3-, 5-year graft and patient survival rates of ABO-incompatible were distinctly lower than that of ABO-compatible group (P < 0.05). Our results suggested that ABO-incompatible liver transplantation might be a life-saving procedure for patients with SHB as a promising alternative operation when ABO-compatible donors are not available and at least bridges the second opportunity for liver retransplantation.
KW - ABO blood-group system
KW - ABO-incompatible
KW - blood group incompatibility
KW - liver failure
KW - liver transplantation
KW - severe hepatitis B
UR - http://www.scopus.com/inward/record.url?scp=84930483020&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84930483020&partnerID=8YFLogxK
U2 - 10.1111/tri.12531
DO - 10.1111/tri.12531
M3 - Article
C2 - 25630359
AN - SCOPUS:84930483020
VL - 28
SP - 793
EP - 799
JO - Transplant International
JF - Transplant International
SN - 0934-0874
IS - 7
ER -